



NETWORK *Notification*

Notice Date: January 1, 2024
To: CareSource Providers
From: CareSource
Subject: Avalon Q3 2023 Quarterly Policy Updates

Summary

CareSource has partnered with Avalon Healthcare Solutions for laboratory benefits management (LBM), including routine testing management (RTM), a post-service pre-payment clinical claim editing program for routine lab testing.

The RTM program is based on ensuring compliance with the lab policies located on [Avalon's website](#).

This notification is intended to provide you notification of changes to the policies listed below. The policies appear on Avalon website upon their effective dates.

Policies

Policy Name	Plans	Effective Date
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024

G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2100 In Vitro Chemoresistance and Chemosensitivity Assays	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2115 Metabolite Markers for Thiopurines Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2119 Diagnostic Testing of Influenza: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2123 Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2150 Biomarkers for Myocardial Infarction and Chronic Heart Failure: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2157 Diagnostic Testing of Common Sexually Transmitted Infections: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2159 B-Hemolytic Streptococcus Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
M2112 Nerve Fiber Density Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	Ohio Marketplace	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024

G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2100 In Vitro Chemoresistance and Chemosensitivity Assays	Ohio Marketplace	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2115 Metabolite Markers for Thiopurines Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2119 Diagnostic Testing of Influenza: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2123 Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2150 Biomarkers for Myocardial Infarction and Chronic Heart Failure: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2157 Diagnostic Testing of Common Sexually Transmitted Infections: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2159 B-Hemolytic Streptococcus Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024

M2112 Nerve Fiber Density Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	Georgia Marketplace	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2100 In Vitro Chemoresistance and Chemosensitivity Assays	Georgia Marketplace	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2115 Metabolite Markers for Thiopurines Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2119 Diagnostic Testing of Influenza: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024

G2123 Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2150 Biomarkers for Myocardial Infarction and Chronic Heart Failure: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2157 Diagnostic Testing of Common Sexually Transmitted Infections: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2159 B-Hemolytic Streptococcus Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
M2112 Nerve Fiber Density Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2100 In Vitro Chemoresistance and Chemosensitivity Assays	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver	Georgia Dual Special Needs (D-SNP)	03/01/2024

Disease: Effective Date: 03/01/2024		
G2115 Metabolite Markers for Thiopurines Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2119 Diagnostic Testing of Influenza: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2123 Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2150 Biomarkers for Myocardial Infarction and Chronic Heart Failure: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2157 Diagnostic Testing of Common Sexually Transmitted Infections: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2159 B-Hemolytic Streptococcus Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
M2112 Nerve Fiber Density Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	Kentucky Marketplace	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024

G2100 In Vitro Chemoresistance and Chemosensitivity Assays	Kentucky Marketplace	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2115 Metabolite Markers for Thiopurines Testing: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2119 Diagnostic Testing of Influenza: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2123 Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2150 Biomarkers for Myocardial Infarction and Chronic Heart Failure: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2157 Diagnostic Testing of Common Sexually Transmitted Infections: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2159 B-Hemolytic Streptococcus Testing: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
M2112 Nerve Fiber Density Testing: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	North Carolina Marketplace	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024

G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2100 In Vitro Chemoresistance and Chemosensitivity Assays	North Carolina Marketplace	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2115 Metabolite Markers for Thiopurines Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2119 Diagnostic Testing of Influenza: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2123 Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2150 Biomarkers for Myocardial Infarction and Chronic Heart Failure: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2157 Diagnostic Testing of Common Sexually Transmitted Infections: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2159 B-Hemolytic Streptococcus Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
M2112 Nerve Fiber Density Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024

G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	West Virginia Marketplace	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2100 In Vitro Chemoresistance and Chemosensitivity Assays	West Virginia Marketplace	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2115 Metabolite Markers for Thiopurines Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2119 Diagnostic Testing of Influenza: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2123 Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024

G2150 Biomarkers for Myocardial Infarction and Chronic Heart Failure: Effective Date: 03/01/2024	West Virginia Marketplace	12/01/2023
G2157 Diagnostic Testing of Common Sexually Transmitted Infections: Effective Date: 03/01/2024	West Virginia Marketplace	12/01/2023
G2159 B-Hemolytic Streptococcus Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
M2112 Nerve Fiber Density Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024

Trial Claim Advice Tool

Providers may use the Trial Claim Advice tool to review claims with laboratory services for adherence and consistency with CareSource laboratory policies. This is a simulation tool and does not guarantee approval or reimbursement of claims. You can access the Trial Claim Advice Tool on the CareSource [Provider Portal](#).

Multi-Multi-P-2589252